Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia
JCI Insight · 2025
DOI: 10.1172/jci.insight.187758 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Madeline G Hemmingsen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics. Hauptthemen laut MEDLINE: Amino Acid Metabolism, Inborn Errors, Transaminases, Mitochondria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methylmalonic acidemia (MMA) is a severe metabolic disorder affecting multiple organs because of a distal block in branched-chain amino acid (BCAA) catabolism. Standard of care is limited to protein restriction and supportive care during metabolic decompensation. Severe cases require liver/kidney transplantation, and there is a clear need for better therapy. Here, we investigated the effects of a small molecule branched-chain amino acid transaminase (BCAT) inhibitor in human MMA hepatocytes and an MMA mouse model. Mitochondrial BCAT is the first step in BCAA catabolism, and reduction of flux through an early enzymatic step is successfully used in other amino acid metabolic disorders. Metabolic flux analyses confirmed robust BCAT inhibition, with reduction of labeling of proximal and distal BCAA-derived metabolites in MMA hepatocytes. In vivo experiments verified the BCAT inhibition, but total levels of distal BCAA catabolite disease markers and clinical symptoms were not normalized, indicating contributions of substrates other than BCAA to these distal metabolite pools. Our study demonstrates the importance of understanding the underlying pathology of metabolic disorders for identification of therapeutic targets and the use of multiple, complementary models to evaluate them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics.
- University Program in Genetics and Genomics.
- Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center; and.
- Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Biomedical Engineering, Duke University Pratt School of Engineering, Durham, North Carolina, USA.
- Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.
Zitieren
APA
Hemmingsen, M. G., Zhang, G. F., Ma, Y., Marchuk, H., Patel, K. R., Chen, T., Li, X., Chapman, M., Collias, S., Lopez-Terrada, D. H., Beasley, J., Stiles, A. R., Chandler, R. J., Venditti, C. P., Young, S. P., Barzi, M., Bissig-Choisat, B., Krafte, D., Newgard, C. B., & Bissig, K. D. (2025). Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia. JCI Insight. https://doi.org/10.1172/jci.insight.187758
Vancouver
Hemmingsen MG, Zhang GF, Ma Y, Marchuk H, Patel KR, Chen T, et al. Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia. JCI Insight. 2025. doi:10.1172/jci.insight.187758
BibTeX
@article{Hemmingsen2025,
author = {Hemmingsen, Madeline G and Zhang, Guo-Fang and Ma, Yunhan and Marchuk, Hannah and Patel, Kalyani R and Chen, Tong and Li, Xinning and Chapman, Mark and Collias, Sabrina and Lopez-Terrada, Dolores H and Beasley, James and Stiles, Ashlee R and Chandler, Randy J and Venditti, Charles P and Young, Sarah P and Barzi, Mercedes and Bissig-Choisat, Beatrice and Krafte, Doug and Newgard, Christopher B and Bissig, Karl-Dimiter},
title = {Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.187758}
}
EUVIMED